MVM invests €15.2m in Valneva SE

- Leading Healthcare Investor MVM Life Science Partners Acquires 7.5% Shareholding in Valneva

- Funds managed by MVM Life Science Partners LLP (“MVM”) to invest a total of €15.2 million in a simultaneous private placement of 2.9 million newly issued shares and purchase of a further tranche of existing shares

- Issue price of €2.60 per share corresponds to the volume weighted average trading price of the previous three trading sessions

- Dr. Bali Muralidhar to join Valneva’s Supervisory Board as MVM representative

Lyon (France), December 1, 2016 – Valneva SE (“Valneva” or “the Company”), a fully integrated, commercial stage biotech company focused on developing innovative lifesaving vaccines, today announced that MVM Life Science Partners LLP ('MVM'), a specialist healthcare investor based in London and Boston with more than $700 million under management, has acquired a 7.5% shareholding in the Company. MVM will be entitled to an investor director representative, to be appointed to Valneva’s Supervisory Board by the next annual shareholders meeting.

Thomas Lingelbach, President and CEO, and Franck Grimaud, Deputy CEO of Valneva, commented, “MVM’s investment in Valneva is a strong endorsement of our growth strategy and an important step in our initiative to broaden our shareholder base. We are delighted to welcome such a renowned healthcare investor on board, who can help us in continuing to develop Valneva by bringing expertise, networks and financial resources.”

Dr. Bali Muralidhar, a partner at MVM, added, “Valneva is uniquely positioned in having deep domain expertise in vaccine discovery, development and commercialisation within one independent company. We look forward to supporting the growth of the current commercial vaccine franchise both organically and inorganically. The company has a rich pipeline of vaccine products in development and we are particularly excited to be part of a company that has the opportunity to bring a novel Lyme vaccine to unserved patients in the US and EU.”

The investment by MVM is being made by means of a combined private placement and share purchase. The transaction is expected to close on December 14, 2016. The issuance of 2,884,615 new primary shares will result in proceeds of €7.5 million for Valneva and will bring the Company’s total number of ordinary shares to 77,582,714. Together with the purchase of a further tranche of shares from undisclosed shareholders of the Company, MVM will own 7.5% of Valneva’s ordinary shares at the close of the combined transaction.

Valneva’s current key shareholders, Groupe Grimaud and BPI France, did not participate in the transaction through any sale or purchase of shares and will still own 15.6% and 9.6%, respectively, of the Company’s ordinary share capital after the transaction. Both shareholders have committed to vote for the appointment of Dr. Bali Muralidhar as a new member of Valneva’s supervisory board in the next Annual General Shareholder meeting, expected to take place in June 2017. In the meantime, Dr. Muralidhar will join the supervisory board as an observer.

Valneva intends to use the net proceeds of the private placement to fund the development of its clinical stage vaccine products and to accelerate worldwide commercialization activities.

About Valneva SE
Valneva is a fully integrated vaccine company that specializes in the development, manufacture and commercialization of innovative vaccines with a mission to protect people from infectious diseases through preventative medicine.

The Company seeks financial returns through focused R&D investments in promising product candidates and growing financial contributions from commercial products, striving towards financial self-sustainability.

Valneva’s portfolio includes two commercial vaccines for travelers: IXIARO®/JESPECT® indicated for the prevention of Japanese encephalitis and DUKORAL® indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC.

The Company has proprietary vaccines in development including candidates against Clostridium difficile and Lyme Borreliosis. A variety of partnerships with leading pharmaceutical companies complement the Company’s value proposition and include vaccines being developed using Valneva’s innovative and validated technology platforms (EB66® vaccine production cell line, IC31® adjuvant).

Valneva is listed on Euronext-Paris and the Vienna stock exchange and has operations in France, Austria, Great Britain, Sweden, Canada and the US with over 400 employees. More information is available at

Valneva SE

Valneva SE
Commercial stage vaccines


DownloadPress Release

Latest News

MVM announces partial sale of its holding in Ambio

MVM Partners announces the partial sale of its holding in Ambio to The Carlyle Group

Alliance Pharma acquires Nizoral rights in APAC region

Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, is pleased to announce that it has agreed to acquire exclusive marketing rights to Nizoral, a medical, anti-dandruff shampoo brand, in Asia-Pacific from Janssen Pharmaceutica NV.

Alliance Pharma receives positive opinion for Diclectin

Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, announces that, following discussions with the Medicines and Healthcare products Regulatory Agency and the Commission on Human Medicines, the Marketing Authorisation Application for Diclectin® is now considered approvable.

Wilson Therapeutics AB announces public offer from Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc., has today, through Alexion Pharma Nordics Holding AB, announced a public cash offer to Wilson Therapeutics’ shareholders for a consideration of SEK 232 per Wilson Therapeutics share in cash (the “Offer”), which corresponds to a total offer value of approximately SEK 6,564 million, based on 28,292,272 shares outstanding.

Clinical study supports the use of Cheetah Medical's technologies

Cheetah Medical, a leader in non-invasive hemodynamic monitoring, has announced the publication of a major clinical study designed to evaluate stroke volume guided resuscitation in ICU patients with severe sepsis and septic shock

Vertos Medical Secures $28m in Latest Round of Funding

Vertos Medical Inc., a leader in the minimally invasive treatment of lumbar spinal stenosis has announced that it has completed a $28 million financing round.